Report Overview

The Chronic Obstructive Pulmonary Disease (COPD) drug market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is progressive and associated to an abnormal response of the lungs to noxious particles or gases. Smoking is the main risk factor of COPD. Exposure to occupational or domestic fumes, or previous infection can also cause the disease. In Kenya, COPD is estimated to cause the same amount of DALYs as ischemic heart disease, stroke and epilepsy indicating that it is grossly underdiagnosed and treated. There is a high prevalence of COPD among women due to the exposure to fumes from wood and charcoal used in cooking.



Market Drivers

The market is majorly driven by the rising prevalence of COPD in Kenya. Chronic Obstructive Pulmonary Disease (COPD) causes substantial burden of disease in low- and middle-income countries, but there are limited data from Africa.A Meta analysis of five spirometry-based studies from Africa reported a mean prevalence of COPD as 13.4%, ranging from 9.4 to 22.1%.

Smoking is the main risk factor for development of Chronic Obstructive Pulmonary Disease. According to WHO, about 86.1% of Kenyan adults are exposed to tobacco smoke in bars and night clubs and 24.8% of youth being exposed at home.

In Kenya, 7.2% of school-going adolescents smoke cigarettes, while 8.5% use other forms of tobacco products. Dyspnoea is the main reason for COPD having the 10th highest morbidity in low- and middle- income countries. Mortality increases with decreasing lung function, infective exacerbations and acute respiratory failure.

High levels of tuberculosis infection in Kenya also increases COPD prevalence.